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Abstract
Measurement of portal pressure is pivotal in the 
evaluation of patients with liver cirrhosis. The mea-
surement of the hepatic venous pressure gradient 
represents the reference method by which portal 
pressure is estimated. However, it is an invasive 
procedure that requires significant hospital resources, 
including experienced staff, and is associated with 
considerable cost. Non-invasive methods that can be 
reliably used to estimate the presence and the degree 
of portal hypertension are urgently needed in clinical 
practice. Biochemical and morphological parameters 
have been proposed for this purpose, but have shown 
disappointing results overall. Splanchnic Doppler 
ultrasonography and the analysis of microbubble contrast 
agent kinetics with contrast-enhanced ultrasonography 
have shown better accuracy for the evaluation of 
patients with portal hypertension. A key advancement 
in the non-invasive evaluation of portal hypertension 
has been the introduction in clinical practice of methods 
able to measure stiffness in the liver, as well as 
stiffness/congestion in the spleen. According to the data 
published to date, it appears to be possible to rule out 
clinically significant portal hypertension in patients with 
cirrhosis (i.e. , hepatic venous pressure gradient ≥ 10 
mmHg) with a level of clinically-acceptable accuracy by 
combining measurements of liver stiffness and spleen 
stiffness along with Doppler ultrasound evaluation. It is 
probable that the combination of these methods may 
also allow for the identification of patients with the most 
serious degree of portal hypertension, and ongoing 
research is helping to ensure progress in this field.
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Core tip: This Editorial analyzes the newest and 
promising methods for estimating portal pressure non-
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invasively in cirrhotic patients with portal hypertension. 
Measurements of liver and spleen stiffness, combined 
with Doppler ultrasound evaluation, allow for the 
identification of patients without clinically-significant 
portal hypertension and are also promising for esti-
mation of the degree of portal pressure in patients with 
portal hypertension.
Bolognesi M, Di Pascoli M, Sacerdoti D. Clinical role of 
non-invasive assessment of portal hypertension. World J 
Gastroenterol 2017; 23(1): 1-10  Available from: URL: http://
www.wjgnet.com/1007-9327/full/v23/i1/1.htm  DOI: http://
dx.doi.org/10.3748/wjg.v23.i1.1
INTRODUCTION
Measurement of portal pressure is pivotal in the 
evaluation of patients with liver cirrhosis. Indeed, 
portal hypertension is a complication of cirrhosis that 
affects prognosis and the natural history (disease 
stage). Portal hypertension is the main etiology under­
lying the opening of collateral circulation and the 
onset of hyperdynamic circulatory syndrome, which 
can result in esophageal varices (EV), gastrointestinal 
bleeding, ascites, hepatorenal syndrome, spontaneous 
bacterial peritonitis and/or hepatic encephalopathy[1]. 
Therefore, upper gastrointestinal endoscopy and 
measurement of portal pressure are recommended 
for patients with suspected liver cirrhosis and portal 
hypertension[1]. Moreover, the measurement of portal 
pressure represents the only valid method currently 
available for evaluation of effectiveness of portal 
hypertension therapies (pharmacological, surgical, 
interventional radiology)[2].
CLINICALLY-SIGNIFICANT PORTAL 
HYPERTENSION
Increase in portal pressure has been shown to 
be clinically significant (clinically significant portal 
hypertension, CSPH) when it corresponds to a 
porto­hepatic gradient of ≥ 10 mmHg[2,3]. CSPH is 
considered the threshold beyond which complications 
like EV and ascites may develop[2,4]. However, in the 
evaluation of portal hypertension, it is not sufficient to 
merely determine the presence or absence of CSPH. 
Indeed, the degree of portal hypertension defines 
different levels of risk, with progressively worse 
prognostic significance.
Risk of EV, ascites and decompensation after 
surgery for hepatocellular carcinoma is associated 
with portal pressure > 10 mmHg, while risk of 
bleeding of EV is associated with a portal pressure 
of ≥ 12 mmHg[5]. Portal pressure > 16 mmHg is 
reported as correlated with survival, first clinical 
decompensation in patients with varices, and higher 
risk of esophageal rebleeding and mortality in patients 
with decompensated cirrhosis; higher than 20 mmHg 
is correlated with failure to control bleeding in patients 
with active bleeding from varices and to mortality, > 
22 mmHg is correlated with mortality in patients with 
alcoholic cirrhosis and acute alcoholic hepatitis, and 
> 30 mmHg is correlated with spontaneous bacterial 
peritonitis[3,5,6]. In contrast, improvement of portal 
hypertension is associated with improved prognosis. 
In particular, a reduction in portal pressure to a level 
of < 12 mmHg, or to at least of 20% of the baseline 
values, is necessary to obtain clinical efficacy of portal 
hypertension therapy[2,7,8]. It is clear, therefore, that 
when portal hypertension is suspected in patients with 
liver cirrhosis, it is not only necessary to know whether 
CSPH is present but also to quantify the level of portal 
hypertension and, further, to evaluate the change in 
portal pressure over time.
MEASUREMENT OF PORTAL PRESSURE: 
THE HEPATIC VENOUS PRESSURE 
GRADIENT
The actual reference method for the measurement of 
portal pressure is measurement of the hepatic venous 
pressure gradient (HVPG), an indirect estimate of 
portal pressure obtained by use of catheterization 
of the hepatic veins. It allows measurement of 
the level of sinusoidal pressure by calculating the 
difference between the pressure in a hepatic vein 
that has been inserted with the occluding catheter 
and free pressure[5,7]. In the cirrhosis condition, portal 
hypertension is mainly due to sinusoidal and post­
sinusoidal hypertension, with the sinusoidal pressure 
corresponding to the pressure in the portal vein. 
Introduction of balloon catheters to this measurement 
approach has resulted in marked improvement in 
reliability of the measurement[9].
HVPG is an indirect method, which is only able 
to correctly evaluate portal pressure in patients with 
increased portal pressure at the sinusoidal level (i.e., 
cirrhosis), and it has no value in patients with pre­
sinusoidal and pre­hepatic portal hypertension. Yet, 
detection of its normality can sometimes help in 
differential diagnosis of those forms of pre­hepatic 
portal hypertension.
With this limitation, HVPG, if executed according to 
the guidelines, is a safe and reproducible technique, 
and has emerged as the reference method for 
measurement of the pressure gradient between the 
portal vein and the inferior vena cava in cirrhosis 
(sinusoidal portal hypertension)[2]. Unfortunately, the 
method is invasive and relies on the commitment 
of significant hospital resources, equating to a 
considerable cost and requiring experienced staff. As 
such, it is routinely performed in only a few centers, 
particularly those specializing in the treatment of portal 
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hypertension[10].
NON-INVASIVE ESTIMATION OF PORTAL 
PRESSURE
Non­invasive methods that can be used reliably to 
determine the presence and estimate the degree 
of portal hypertension have been in great demand 
for at least 30 years. Despite substantial efforts to 
generate such a method, up until a few years ago only 
disappointing and unsatisfactory results were obtained.
Since the primary cause of portal hypertension 
is the mechanical increase in intrahepatic resistance 
due to fibrosis and distortion of liver architecture, it is 
reasonable to assume that non­invasive parameters 
of liver fibrosis may indicate the presence of portal 
hypertension.
ESTIMATION OF PORTAL 
HYPERTENSION BY BIOCHEMICAL AND 
MORPHOLOGICAL PARAMETERS
A number of the biochemical and morphological 
parameters that have been proposed for evaluation 
of the degree of liver fibrosis have been analyzed 
for their potential in use for the evaluation of 
portal hypertension and/or the presence of EV[11]. 
Even if there is a broad correlation between these 
indices and portal pressure or the presence of EV, 
confirming the role of liver fibrosis in the genesis of 
this condition, it is a fact that the low coefficients 
of the correlations do not support clinical use of 
these parameters for this purpose. Various indices 
have also been proposed[3,12,13]. The platelet count/
spleen diameter ratio (Plt/Spl) was reported to be 
independently associated with the presence of EV, 
as shown in a multivariate analysis. A Plt/Spl cut­
off value of 909 had 100% negative predictive value 
for diagnosis of EV[14,15]. Another study determined 
that this parameter is also related to the presence of 
portal hypertension[16]. A model combining albumin, 
aspartate aminotransferase (AST) and the international 
normalized ratio (INR) had an area under the receiver 
operating characteristic curve (AUROC) of 0.952 
for prediction of CSPH in a group of patients with 
compensated cirrhosis[17].
In a study by Sebastiani et al[18], a combination of 
the Lok index (an index derived by AST and alanine 
aminotransferase (ALT) levels, platelet counts and 
prothrombin time (PT)­INR; using a cut­off of 1.5) 
and the Forns’ index (an index derived by age, platelet 
counts, gamma­glutamyl transferase (GGT) and 
cholesterol; using a cut­off of 8.8) had an AUROC 
of 0.80 (95%CI: 0.76­0.84) and a high negative 
predictive value (> 90%) for excluding clinically­
relevant EV[18].
Overall, the results for the proposed parameters 
and indices have not been satisfactory[3]. Serum 
markers may be useful as a first-line tool to identify 
cirrhotic patients in whom the risk of clinically­
relevant EV is trivial[17]. However, the possibility of 
replacing upper endoscopy with simple serum non­
invasive markers is still not practical for the vast 
majority of patients[3,11,13,17,18]. Accordingly, the 
biochemical/morphological tests may be of help to 
diagnose patients with suspected CSPH, but not to 
estimate the degree of portal pressure. These tests 
do not allow for clinical decisions on their own, nor 
can they be used alone in a clinical context; although, 
they may be sufficient in use as a first­level test[19] 
(laboratory tests require no clinical skillfulness, dis­
tinctive from Doppler ultrasound and measurement 
of tissue stiffness), but their use would not exempt a 
clinician from undertaking further analysis with more 
accurate tests.
ESTIMATION OF PORTAL 
HYPERTENSION BY DOPPLER 
ULTRASOUND TECHNIQUES
The introduction of ultrasound and Doppler techniques 
generated great expectations in the 1990s for non­
invasive assessment of portal hypertension. Doppler 
ultrasound evaluation was a major step forward in the 
clinical evaluation of patients with portal hypertension. 
Indeed, many parameters indicating the presence of 
portal hypertension could be identified non-invasively, 
including the presence of collateral vessels, spleen 
enlargement, ascites, change in the portal vein 
parameters (e.g. increase in diameter, disappearance 
of caliper variation during respiration, decrease in 
blood flow velocity, increase in the congestion index), 
increase in hepatic and splenic arterial resistance 
indices, and decrease in the damping index of hepatic 
veins[5,12,20­22]. Scores obtained by the combinations 
of measuring portal vein blood velocity, portal 
vein diameter, the hepatic artery resistance index 
and splenic artery resistance index[4,12,23­26] were 
proposed and demonstrated to be useful in the 
clinical monitoring of patients with cirrhosis and portal 
hypertension.
Some of these parameters, such as the presence 
of collateral circulation in patients with cirrhosis, can 
be considered as having a specificity of 100% for the 
diagnosis of CSPH[2]; although, all of these parameters 
have low diagnostic sensitivity for identifying the 
condition.
In patients with known cirrhosis, Doppler ultrasound 
has > 80% specificity for diagnosis of CSPH, but 
sensitivity does not exceed 40%­70%, particularly 
in compensated patients[5]. Therefore, while the 
presence of one or more Doppler ultrasound signs can 
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ESTIMATION OF PORTAL PRESSURE 
BY THE MEASUREMENT OF LIVER 
STIFFNESS
Another important advancement in the non­invasive 
assessment of portal hypertension has been the 
introduction of non­invasive measurement of liver 
stiffness (LS) by transient elastography (TE). Originally 
proposed and designed as a non­invasive approach 
for detecting the presence of fibrosis in the liver, after 
initial doubts, the method has gradually imposed itself 
as a routine method used in the clinical evaluation 
of patients with chronic liver disease. TE has proven 
sensitive for estimating the absence of liver fibrosis 
or the presence of high­degree liver fibrosis, yet 
patients with moderate fibrosis remain more difficult 
to assess[26]. TE has also been shown to be related to 
the degree of portal pressure[10,38,39]. Such a correlation 
is somewhat expected because liver fibrosis is the 
first and main determinant both of tissue stiffness 
and of intrahepatic resistance to portal blood flow[3]. 
LS can increase independently of fibrosis due to 
food ingestion, inflammation, cholestasis and liver 
congestion[3]. Even with the limitations cited above, a 
number of studies have demonstrated that the related 
method allows not only for estimation of liver fibrosis 
but also determination of CSPH presence[13,40,41]. In 
patients with chronic liver disease, LS can predict CSPH 
(HVPG ≥ 10 mmHg) with a very high accuracy, having 
an AUROC of 0.945 (95%CI: 0.904­0.987); when 
the cut­off value was set at 21 kPa, this procedure 
accurately predicted CSPH in 92% of the patients for 
whom LS was successful[40]. Lemoine et al[41] confirmed 
that LS can predict CSPH, but highlighted that the cut­
off is higher, with a better performance, in alcoholic 
patients; in particular, the AUROC for diagnosis of 
CSPH was reported as 0.76 ± 0.07 in patients with 
hepatitis C virus (HCV) infection (best cut­off at 20.5 
kPa) and 0.94 ± 0.03 (best cut­off at 34.9 kPa) in 
alcoholic patients[41].
These results justify the proposal to use this 
method in clinical practice for identifying patients with 
CSPH[5]. Therefore, TE can be used as a screening 
method for CSPH in patients with compensated liver 
cirrhosis[2,5].
Vizzutti et al[39] showed that the correlation between 
LS and portal pressure in cirrhosis is very good up 
to 10­12 mmHg, while it is substantially lacking for 
higher values. This finding has been explained by the 
fact that ­ while in the early stages of the disease the 
main factor determining portal hypertension is liver 
fibrosis, therefore it is well related to portal pressure 
­ once CSPH is established, the progression of portal 
hypertension depends not only on liver fibrosis but 
also on other factors, especially those related to the 
hyperdynamic circulation, the splanchnic vasodilatation 
and the resistance in portosystemic collaterals[42­44]. 
establish the presence of CSPH, their absence cannot 
exclude it. Moreover, Doppler ultrasound is not useful 
for evaluating the effect of pharmacological therapy 
on portal hypertension, as vasoactive drugs used in 
the therapy of portal hypertension modify Doppler 
parameters (i.e., vascular blood velocity, resistance 
indices) per se, in a manner independent of the final 
modification of portal pressure.
On the contrary, Doppler parameters may have 
major utility in the evaluation of the effect of sur­
gical therapy and of liver transplantation on portal 
hypertension. Indeed, in these conditions, normalization 
of portal hemodynamics and of splenic Doppler 
resistance indices has been proposed as confirmatory 
for having achieved a good resolution of portal 
hypertension after surgery[27].
Thus, although indispensable in the evaluation 
and monitoring of patients with cirrhosis and portal 
hypertension, Doppler ultrasonography cannot be used 
on its own as a screening method to exclude CSPH, 
nor as a method for monitoring portal pressure over 
time. Doppler ultrasound, however, does detect signs, 
such as portal­collateral circulation, ascites and portal 
vein thrombosis, that, if present, allow for a certain 
diagnosis of CSPH. 
Color Doppler ultrasonography is a useful non­
invasive modality for assessing gastric, duodenal and 
rectal varices[28­31]. Contrast­enhanced ultrasonography 
analysis of transit time of microbubble contrast 
agent through the liver has demonstrated that a 
decrease in the transit time between the hepatic vein 
and the hepatic artery or the portal vein (a sign of 
porto­hepatic shunting) is related to the degree of 
portal hypertension in cirrhosis[12,21,32]. Moreover, a 
relation has been reported for the presence of portal 
hypertension and a number of other parameters 
derived by the analysis of time­intensity curves of 
contrast agent in the various liver structures; these 
parameters include regional hepatic perfusion[33], 
portal vein/hepatic artery strength ratio, area under 
the portal vein/hepatic artery time­intensity curve 
ratio, and portal vein/hepatic artery wash­in perfusion 
slope ratio[34]. Unfortunately, most of the correlations 
reported between these parameters and portal 
pressure are weak, indicating that they cannot predict 
the presence of CSPH in single patients with sufficient 
accuracy.
Recently, a new non­invasive approach to quantify 
portal pressure has been proposed that is based 
upon subharmonic emission from ultrasound contrast 
agent[35,36]. The changes of subharmonic signal 
amplitude are reported as correlating with portal 
pressure changes[36]; moreover, Eisenbrey et al[37] 
demonstrated that subharmonic­aided pressure 
estimation (SHAPE) was in good overall agreement with 
HVPG (r = 0.82). This method seems promising and 
deserves further study. 
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Unfortunately, these factors are not estimated by 
LS[10,16,39].
According to the collective data, TE can be very 
useful for ruling out or ruling in CSPH[5]; however, the 
technique is not accurate enough to replace HVPG in 
quantifying the exact severity of portal hypertension[5]. 
Furthermore, TE is unlikely to be useful in monitoring 
hemodynamic response to drug therapy, the effect of 
which is mediated primarily by decreases in splanchnic 
blood flow and partially by modifications in hepatic 
and collateral resistance, and not by improvements in 
hepatic fibrosis and liver stiffness[38].
LS has been demonstrated to be as effective as 
HVPG for predicting clinical decompensation and 
portal hypertension­related complications in patients 
with chronic liver disease[45]. The usefulness of LS 
in predicting portal hypertensive complications was 
confirmed by Kitson et al[46].
In recent years, additional techniques have been 
proposed for the evaluation of LS, each of which 
appear to overcome some of the limitations presented 
by traditional TE[47,48]; these include acoustic radiation 
force impulse imaging (ARFI) and shear­wave velocity 
estimation. In particular, the real­time shear­wave 
elastography (SWE) allows for real­time viewing of the 
area under investigation, contrary to TE which is done 
blindly, as well as integration of the assessment of TE 
with traditional ultrasound and Doppler[1,12,21,47,49­51]. 
In this context, it may be possible to integrate 
the measurement of LS with Doppler ultrasound 
parameters and, therefore, improve the accuracy of 
portal hypertension evaluation. The reported technical 
success rate of SWE is significantly better than that 
of TE[52]. Choi et al[53] also proposed that non­invasive 
measurement of LS by SWE may be useful for 
monitoring efficacy of the medical therapy of portal 
hypertension.
ESTIMATION OF PORTAL 
HYPERTENSION BY THE MEASUREMENT 
OF SPLEEN STIFFNESS
A very noteworthy advancement in this field is the 
application of non­invasive evaluation of parenchymal 
stiffness (via TE, ARFI and SWE) in the spleen[16,54,55]. 
An interesting study[16] showed that in patients with 
HCV­related cirrhosis, there is a very good correlation 
between HVPG and spleen stiffness (SS) (r2 = 0.78), 
with a correlation that is maintained even when portal 
pressure is > 10 mmHg, which contrasts with LS. This 
study suggests that SS increases in close parallel with 
the progression of portal hypertension from the early 
to the late stages of cirrhosis[16].
Similarly to LS, SS measurement has also been 
reported as useful for predicting of clinical complications 
in compensated cirrhosis[56]. In patients with HCV­
related cirrhosis, a SS and model for end­stage liver 
disease (MELD) predictive model represented an 
accurate predictor of clinical decompensation, with 
accuracy at least equivalent to that of HVPG[56]. A value 
for SS of < 54 kPa ruled out the risk of complications 
in the subsequent 2 years[56]. SS has been shown to 
decrease after orthotopic liver transplantation, when 
portal hypertension is resolved[57]. This is a behavior 
similar to splenic resistance indices[27].
Although not all of the subsequent studies yielded 
such reassuring results[51,52], this study highlighted 
that spleen parameters probably reflect the levels 
of portal hypertension more accurately, due to the 
peculiar modifications that occur in the spleen during 
portal hypertension as a result of congestion and 
hyperplasia[58]. In cirrhosis, splenomegaly is not only 
due to passive congestion but also to tissue hyperplasia, 
and is characterized by a combination of angiogenesis, 
fibrogenesis, and enlargement and hyperactivation of 
the splenic lymphoid compartment[16,58]. This condition 
of hyperplasia, with increased flow, participates in 
the hyperdynamic circulatory syndrome of portal 
hypertension[58].
Stiffness and hemodynamics of the spleen are 
probably sensitive sensors of portal pressure and of 
portal vein resistance. Therefore, it seems that the 
next route to follow will be the combination of SS with 
the Doppler splenic resistance indices, and possibly 
platelet count and spleen size. Indeed, individually, 
these parameters have shown better accuracy in 
the prediction of portal hypertension. SS is probably 
related to splenic congestion due to portal hypertension 
in an organ with a rigid capsule. The platelet count/
spleen diameter ratio is probably the simplest index 
for determining the presence of portal hypertension 
and EV[14­16,59,60]. Doppler splenic resistance indices 
are related to portal blood flow resistance and to 
HVPG[22,24].
As evidence for the central role of splenic hemo­
dynamics in portal hypertension, a few studies have 
shown the usefulness of combining the value of LS 
with splenic parameters to improve the identification 
of patients with portal hypertension. Among these 
parameters are the LS­spleen diameter to platelet 
ratio score (LSPS)[13,16,59] and the portal hypertension 
risk score, the latter of which combines LS, sex and 
spleen diameter/platelet count ratio[61]. This portal 
hypertension risk score had the highest AUROC value 
(0.935), as compared with LS alone or LSPS, for 
identifying patients with CSPH.
LIMITATIONS OF LS AND SS 
MEASUREMENT
A limitation of this method is the significant number of 
patients for whom the measurement of LS and/or SS 
could not be completed or yielded unreliable results. 
Reportedly, valid measurement of LS is not obtained 
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in approximately 20% of patients[16,19,47]. TE cannot 
be performed in patients with ascites, and the failure 
rate of TE is generally higher in obese patients[47]. 
Aminotransferase flares, food intake, extrahepatic 
cholestasis, steatosis, increased central venous 
pressure and the use of beta­blockers can influence 
the accuracy of LS assessment by TE[36,62].
Moreover, LS and SS measurement are considered 
reliable for estimating portal hypertension only when 
the coefficient of variation among the successful 
measurements in a single patient is low[51,52]. In the 
study by Elkrief et al[52], the designation of excellent 
accuracy (i.e., patients with variation coefficient of 
TE measurement < 10%) was achieved in < 50% 
of the patients. Procopet et al[51] proposed that 
SWE measurement of LS can be considered “highly 
reliable” only when measurements have a coefficient 
of variation < 10% and a depth of measurement < 
5.6 cm; when these criteria are fulfilled, the rate of 
patients considered well-classified for the presence or 
absence of CSPH is close to 100%.
MAGNETIC RESONANCE IMAGING AND 
COMPUTED TOMOGRAPHY
Other methods have been proposed for non­invasive 
assessment of LS related to portal hypertension, 
namely magnetic resonance elastography, quantita­
tive magnetic resonance imaging and computed 
tomography (CT). Although very interesting, at 
present these methods cannot be recommended as 
routine for measuring LS and SS. Magnetic resonance 
elastography can decompose tissue viscoelastic 
parameters into different components, including 
stiffness, elasticity and viscosity, allowing for better 
differentiation of fibrosis from congestion[63]. CT has 
the hypothetical capacity to assess portal pressure by 
using computational fluid dynamic modeling[64], and 
has already been proposed for use in evaluation of the 
fractional flow coronary reserve[65]. While magnetic 
resonance techniques are very promising[66,67], they are 
too expensive and the use of CT also seems impractical 
due to the high cost and the time­consuming nature of 
Patients with compensated 
advanced chronic liver disease 
Routine blood test (platelet count) 
and abdominal DDU
Platelets ≥ 150 × 109/L; Spleen 
size < 13; No DDU sign of 
portal hypertension
LS: TE < 13.6 kPa 
SS: TE < 40 kPa  
LS: TE 13.6-25 kPa 
(13.6-35 kPa in 
alcoholic etiology)
SS: TE 40-53 kPa  
LS: TE > 25 kPa
(> 35 kPa in 
alcoholic etiology)
SS: TE > 53 kPa     
LS and SS 
measurements: 
inconclusive
No CSPH
Indeterminate:
suspect CSPH
CSPH
No variceal 
screening (avoid 
endoscopy).
No HVPG 
measurement.
Continue periodic 
follow-up
Variceal screening 
(perform 
endoscopy).
Possibly HVPG 
measurement
Variceal screening 
(perform 
endoscopy).
Possibly HVPG 
measurement
Individualize 
diagnostic 
path: consider 
variceal screening 
and HVPG 
measurement
Individualize 
diagnostic path: if 
CSPH cannot be 
excluded: variceal 
screening (perform 
endoscopy) 
and HVPG 
measurement
Variceal screening 
(perform endoscopy).
Possibly HVPG 
measurement
CSPH
LS and SS 
measurement 
not necessary
Measure LS 
and SS
Consider other 
noninvasive 
methods: i.e. , 
MRI, CEUS, 
SHAPE
Platelets < 150 × 109/L;
No DDU sign of portal 
hypertension
Platelets < or ≥ 150 × 109/L;
Spleen size ≥ 13; DDU sign 
of portal hypertension
Figure 1  Hypothetical algorithm of non-invasive methods for screening and evaluation of clinically-significant portal hypertension and to discriminate 
patients with or without a need for endoscopic screening. CEUS: Contrast-enhanced ultrasonography; CSPH: Clinically-significant portal hypertension; DDU: 
Duplex Doppler ultrasonography; HVPG: Hepatic venous pressure gradient; LS: Liver stiffness; MRI: Magnetic resonance imaging; SHAPE: Subharmonic-aided 
pressure estimation; SS: Spleen stiffness; TE: Transient elastography.
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the computational fluid dynamic modeling. 
NON-INVASIVE ESTIMATION OF THE 
PRESENCE OF EV
A number of studies have shown that LS and SS 
would also be able to identify, with acceptable 
accuracy, patients with EV at risk of bleeding[16,59­61,68]. 
The findings of these studies, however, have been 
contradicted by other research groups[13,52,69]. The 
identification of patients with risk of bleeding from EV 
may be better with the measurement of SS[16,70,71], and 
particularly as related to LS[16,60].
Considering that the measurement of LS and 
SS can be considered a good method to identify 
patients with CSPH, and that EV develops only in the 
presence of CSPH, it may be reasonable to propose 
the measurement of LS and SS as a screening method 
for identifying chronic liver disease patients with HVPG 
< 10 mmHg (these patients should not have EV). 
Also, it is important to note that CSPH is a necessary, 
but not sufficient, condition for development of EV[19]. 
Therefore, measurement of LS and SS can exclude the 
need for a screening esophagogastroduodenoscopy, 
but cannot identify who among the patients with CSPH 
is at risk of esophageal bleeding[1,59,72].
According to the Baveno VI criteria, TE and platelet 
count may be used to discriminate such patients, 
without the need for screening varices[2]. On the other 
hand, imaging analyses have shown that collateral 
circulation is sufficient for ruling­in CSPH in patients 
with compensated advanced chronic liver diseases of 
all etiologies[2].  
A hypothetical algorithm of non­invasive methods for 
screening and evaluation of CSPH and to discriminate 
patients with or without a need for screening varices is 
presented in Figure 1.
CONCLUSION
According to the data published to date in the publicly 
available literature, it appears possible to rule­out 
CSPH with a clinically­acceptable accuracy through the 
combination of LS and SS measurements[10,16,50,59,73] 
along with Doppler ultrasound evaluation. It is pro­
bable that the combination of these methods may 
also allow for the identification of patients with the 
most serious degree of portal hypertension. Indeed, 
progress is being made in this field.
To conclude, however, advancement in the non­
invasive evaluation of portal hypertension has included 
the introduction of methods to clinical practice that 
are able to measure stiffness in the liver and stiffness/
congestion in the spleen. These methods, combined 
with Doppler ultrasound evaluation, allow for the 
identification of patients without CSPH. They are also 
promising for their ability to estimate the degree of 
portal pressure in patients with CSPH.
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